Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M105325200 on September 10, 2001

J. Biol. Chem., Vol. 276, Issue 46, 43455-43462, November 16, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/46/43455    most recent
M105325200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, Y.-Y.
Right arrow Articles by Talmage, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, Y.-Y.
Right arrow Articles by Talmage, D. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Apolipoprotein E Inhibits Serum-stimulated Cell Proliferation and Enhances Serum-independent Cell Proliferation*

Yuan-Yuan HoDagger §, Richard J. DeckelbaumDagger , Yachi ChenDagger ||, Tikva Vogel**, and David A. TalmageDagger DaggerDagger

From the Dagger  Institute of Human Nutrition and the  Department of Pediatrics, Columbia University, New York, New York 10032 and ** Biotechnology General Limited, Rehovot 76326, Israel

Received for publication, June 8, 2001, and in revised form, September 6, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Independently of its role in lipid homeostasis, apolipoprotein E (apoE) inhibits cell proliferation. We compared the effects of apoE added to media (exogenous apoE) with the effects of stably expressed apoE (endogenous apoE) on cell proliferation. Exogenous and endogenous apoE increased population doubling times by 30-50% over a period of 14 days by prolonging the G1 phase of the cell cycle. Exogenous and endogenous apoE also decreased serum-stimulated DNA synthesis by 30-50%. However, apoE did not cause cell cycle arrest; both apoE-treated and control cells achieved equivalent saturation densities at 14 days. Further analyses demonstrated that exogenous and endogenous apoE prevented activation of MAPK but not induction of c-fos expression in response to serum growth factors. Endogenous (but not exogenous) apoE altered serum concentration-dependent effects on proliferation. Whereas control (non-apoE-expressing) cell numbers increased with increasing serum concentrations (1.6-fold for every 2-fold increase in serum), apoE-expressing cell numbers did not differ as serum levels were raised from 2.5 to 10%. In addition, in low serum (0.1%), apoE-expressing cells had elevated DNA synthesis levels compared with control cells. We conclude that apoE does not simply inhibit cell proliferation; rather, the presence of apoE alters the response to and requirement for serum mitogens.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apolipoprotein E (apoE)1 plays an important role in the progression of atherosclerosis (1), and different isoforms are associated with varying risks of Alzheimer's disease (2). ApoE is a major protein component of several classes of plasma lipoproteins and is capable of binding to a number of other molecules, including cell-surface lipoprotein receptors and heparan sulfate proteoglycans (1, 3). Although apoE can also influence cell proliferation (4-6), research efforts have focused on determining the mechanisms by which apoE affects lipid metabolism, specifically by facilitating lipoprotein transport, promoting cell cholesterol efflux, and enhancing intracellular cholesteryl ester and triglyceride hydrolysis (7-10).

ApoE can reach cells from two sources: exogenous apoE (defined as apoE synthesized or provided by a remote source such as plasma apoE or apoE added to experimental media), usually as a component of lipoproteins, or endogenous apoE (defined as apoE produced by cellular apoE gene expression). Since apoE binds to lipids and other molecules (1, 3, 11), exogenous apoE and endogenous apoE can potentially encounter and interact with different groups of molecules in the extracellular environment compared with the intracellular environment. For example, exogenous apoE binds to cell-surface apoE receptors and mediates endocytosis, whereas endogenous apoE is mainly associated with Golgi compartments (1, 12). Thus, it is likely that following endogenous synthesis, apoE has different effects on cell function compared with apoE entering cells from the extracellular environment. In macrophages, exogenous apoE is much less effective than endogenous apoE in promoting cholesterol efflux (7, 13). Although exogenous apoE and endogenous apoE are capable of interacting with cells differently, they both can bind the same cell-surface components such as heparan sulfate proteoglycans (3), thereby exerting similar biological effects.

Exogenous apoE affects the proliferation of various cell types (4-6). Cell proliferation is controlled by protein kinase-based signaling pathways linking cell-surface mitogen receptors with various targets within the cell, including critical transcription regulators. Exogenous apoE has been shown to affect the activities of several protein kinases known to be involved in transmitting mitogenic stimuli, including protein kinases A and C and mitogen-activated protein kinases (MAPKs) (6). On the other hand, endogenous apoE expression is controlled by growth state (14), and/or it is tightly coupled to cell differentiation (15, 16). Endogenous apoE also alters cellular signaling and protein kinase activity (17, 18). The question of whether exogenous apoE and endogenous apoE have similar effects on cell proliferation or differentiation has not been addressed directly in the same cell type.

Previous studies have examined the inhibitory effects of exogenous apoE on short-term cell proliferative responses in the presence of serum stimuli (4-6). In this study, we determined the effects of exogenous apoE and endogenous apoE on cell proliferation under conditions of both serum deprivation and serum stimulation. To compare the effects of exogenous apoE and endogenous apoE on proliferation in the same cell type, we stably expressed apoE in a rat fibroblast cell line (F111 cells) that normally does not express apoE. The proliferation properties of parental F111 cells have been previously characterized in detail (19-21). Cells expressing the apoE transgene were defined as E+ cells, in contrast to E- cells carrying only the control plasmid (encoding hygromycin resistance). Responses of cells to serum were determined in the presence or absence of exogenous apoE. Our results indicate that although exogenous apoE and endogenous apoE exhibit similar effects on cell proliferation at a fixed serum concentration, cell proliferative responses to apoE differ dramatically under serum-deprived versus serum-stimulated conditions.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Purified lipid-free apoE was used for experiments. [3H]Thymidine and ECL Western blotting reagents were purchased from Amersham Pharmacia Biotech, and [32P]dCTP was purchased from PerkinElmer Life Sciences. High-glucose (4.5 mg/ml) Dulbecco's modified Eagle's medium (DMEM) was obtained from Cellgro (carried by Fisher). Calf serum was obtained from Hyclone Laboratories (Logan, UT). Penicillin/streptomycin/glutamine mixture (100×: 10,000 units/ml penicillin G sodium, 10,000 µg/ml streptomycin sulfate, 29.2 mg/ml L-glutamine, and 10 mM sodium citrate in 0.14% NaOH) and trypsin were purchased from Life Technologies, Inc. Phosphate-buffered saline (PBS), diethyl pyrocarbonate, and CsCl2 were purchased from Sigma. Hygromycin B was purchased from Roche Molecular Biochemicals. Monoclonal anti-phosphotyrosine antibody 4G10 was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). Polyclonal anti-MAPK and monoclonal anti-phospho-MAPK antibodies were purchased from New England Biolabs Inc. (Beverly, MA). Monoclonal anti-apoE antibody E10 was a generous gift from Drs. E. Krul and G. Schonfield (University of Washington). Horseradish peroxidase-labeled secondary antibodies were purchased from Amersham Pharmacia Biotech and New England Biolabs Inc.

Plasmids-- An apoE expression vector in which the human apoE3 cDNA is expressed from the cytomegalovirus immediate-early promoter was a generous gift from Dr. T. Mazzone (University of Chicago) (33). The hygromycin resistance gene cloned into the plasmid pbeta hygro was regulated by the rat actin promoter (34). Plasmids were transfected into competent Escherichia coli strain DH5 and purified on QIAGEN columns or by CsCl2/EtBr banding (35).

Cells-- Rat F111 embryonic fibroblasts were maintained in high-glucose DMEM containing 10% calf serum and 100 units/ml penicillin G sodium plus 100 µg/ml streptomycin sulfate. ApoE-expressing cell lines were generated by cotransfecting F111 fibroblasts with the apoE3 expression vector and pbeta hygro using calcium phosphate-mediated DNA precipitation (36). Control cell lines were generated in parallel by transfecting the parental cells with pbeta hygro alone. Hygromycin-resistant cells were selected for 1 week in high-glucose DMEM supplemented with 10% calf serum, 100 units/ml penicillin G sodium plus 100 µg/ml streptomycin sulfate, and 200 µg/ml hygromycin and then maintained in the same medium with reduced hygromycin concentrations (100 µg/ml). Three apoE-expressing (E+) and three control (E-) clones were expanded into cell lines and used for experiments. Similar results were obtained with each clone.

Immunoblots-- For detection of apoE synthesis and secretion, cells (60% confluence) were cultured for 24 h in serum-free medium. Both the conditioned medium (concentrated by Amicon Centriprep concentrators, molecular mass cutoff of 10,000 Da) and whole cell extracts (following lysis in 150 mM NaCl, 1% Nonidet P-40, and 50 mM Tris, pH 8.0) were resolved by SDS-12% polyacrylamide gel electrophoresis, followed by electrophoretic transfer of proteins to nitrocellulose membranes. ApoE was detected by incubating membranes with the monoclonal anti-human apoE antibody (E10, 1:2000 dilution in Tris-buffered saline, 0.1% (v/v) Triton X-100, 1% (w/v) nonfat milk, and 0.1% (w/v) sodium azide). Bound primary antibodies were visualized with horseradish peroxidase-conjugated rabbit anti-mouse secondary antibodies and ECL reactions (37). To determine MAPK activity, cell extracts were resolved electrophoretically on SDS-10% polyacrylamide gels and transferred to membranes that were probed with primary antibodies specific to MAPK (1:2000 dilution) or phosphorylated MAPK (1:2000 dilution), followed by incubation with horseradish peroxidase-labeled secondary antibodies and ECL reactions for the detection of total and activated MAPK levels.

Microscopy-- Cell morphology was examined under an Olympus CK2 inverted microscope, and images were recorded by an Olympus C-35-AD-4 camera. The differential interference contrast images were taken under magnification × 100. For experiments aimed to identify the Golgi regions, cells maintained in coverslip bottom dishes were fixed and incubated with 10 mM NBD-C6 dissolved in DMEM containing 0.68 mg/ml fatty acid-free bovine serum albumin for 20 min at 37 °C. Cells were then washed with DMEM for 30 min at 37 °C and submitted for imaging analysis. For identifying the intracellular neutral lipid, cells in coverslip bottom dishes were incubated with 100 ng/ml Nile red and observed immediately. For apoE immunostaining, cells in coverslip bottom dishes were fixed for 30 min with 2% formaldehyde and then washed four times with PBS. Cells were permeabilized with saponin (5% calf serum, 500 µg/ml saponin, and 20 mM glycine in PBS) for 20 min. Prior to incubation, the anti-apoE antibody was pre-absorbed with E- cell protein extracts to reduce nonspecific binding. ApoE immunodetection was performed as follows: 1) monoclonal anti-apoE primary antibody E10 (1:200 dilution) incubation (1 h); 2) three washes with 5% calf serum and 500 µg/ml saponin in PBS (5 min/wash); 3) rhodamine-conjugated goat anti-mouse IgG secondary antibody (1:500 dilution in 5% calf serum and 500 µg/ml saponin in PBS) incubation (1 h); and 4) two washes with 5% calf serum and 500 µg/ml saponin in PBS (5 min/wash) and one wash with PBS (10 min). For actin staining, formaldehyde-fixed cells were extracted by acetone (-20 °C, 3-5 min), followed by two PBS washes and a 25-min incubation in PBS and 1% bovine serum albumin blocking solution. Cells were then stained with actin-BODIPY FL phallacidin (Molecular Probes, Inc., Eugene, OR) at 1:40 dilution in PBS and 1% bovine serum albumin for 20 min. Fluorescent images were obtained using a Zeiss LSM410 confocal laser scanning system attached to a Zeiss Axiovert 100TV inverted microscope. For observation of fluorescence signals based on the excitation/emission wavelengths of the dyes (rhodamine, 570/590 nm; Nile red, 552/636 nm; NBD-C6, 466/536 nm; and phallacidin, 505/512 nm), appropriate combinations of excitation laser and emission filter settings were used. Images were recorded with a Pentium PC computer with Zeiss LSM software for image enhancement and analysis.

Cell Proliferation Rates-- Cells (500/well) were plated in 12-well tissue culture plates (Corning Inc., Corning, NY), and cell number was determined from days 3 to 14. Media (with or without apoE) were changed every 3 days throughout the course of the experiments. For cells incubated with exogenous apoE, 10 µg/ml purified lipid-free apoE was added at every media change (every 3 days). At the indicated time points, cells were trypsinized and detached from the plates, and cell number was counted using a hemocytometer. Results represent three parallel experiments.

Fluorescence-activated Cell Sorter Analyses-- 105 cells suspended in 50 µl of PBS with 3% calf serum were mixed with 1 ml of 80% ethanol and incubated at 4 °C for 30 min. Cells were then pelleted and resuspended in 500 µl of 0.1 mg/ml propidium iodide and 0.6% Nonidet P-40, followed by incubation with 500 µl of 2 mg/ml RNase A at room temperature for 30 min in the dark.

DNA Synthesis-- For experiments measuring DNA synthesis, 1 µCi/ml [3H]thymidine was added to the experimental medium and incubated with cells for 40 h to label the newly synthesized DNA. At the end of the incubation, cells were placed on ice and washed twice with ice-cold PBS, and cell macromolecules including DNA were precipitated for 1 h with ice-cold 10% trichloroacetic acid. Cell precipitates were washed twice with ice-cold 10% trichloroacetic acid to remove free [3H]thymidine and then dissolved in 1 N NaOH (37 °C, 2 h). Trichloroacetic acid-insoluble radioactivity was quantified by scintillation counting. Experiments were repeated three times, and similar results were obtained.

RNA Extraction and Gel Electrophoresis-- Cells were plated in 100-mm tissue culture dishes in the growth medium overnight. After experimental treatments (2.5% calf serum ± 10 µg/ml apoE), cells were washed twice at room temperature with 0.1% diethyl pyrocarbonate-treated PBS and then harvested in Trizol reagent (3 ml/dish; Life Technologies, Inc.). RNA was extracted following the manufacturer's instructions. RNA concentration was determined by spectrophotometry at A260. RNA (10 µg/lane) was dissolved in water and ethidium bromide-containing sample buffer (5 Prime right-arrow 3 Prime, Inc., Boulder, CO), followed by boiling in a water bath for 5 min. Samples were loaded and resolved on 1.2% agarose gels (containing 40 mM MOPS, pH 7.0, 10 mM acetate, and 1.1 M formaldehyde) for 4 h at 100 V. After electrophoresis, the gels were examined under UV light to ensure equivalent RNA loading and integrity. Gels were then gently washed at room temperature with diethyl pyrocarbonate-treated water for 30 min to remove ethidium bromide.

Northern Blot Analyses-- RNA samples on gels were transferred to nylon membranes (Stratagene, La Jolla, CA) in 10× SSC (1.5 M NaCl and 0.15 M trisodium citrate-2H2O, pH 7.0) overnight. The membranes were then irradiated with UV light (1200 J) to cross-link the RNA to the membrane. 32P-Labeled DNA probes were prepared by the random priming method (38) using [alpha -32P]dCTP. Nylon membranes were prehybridized for 15 min and hybridized to radioactively labeled c-fos or L30 probes for 1 h at 65 °C in QuikHyb hybridization solution (Stratagene) and 100 µg/ml salmon sperm DNA. Membranes were washed twice (15 min/wash) with 2× SSC containing 0.1% (w/v) SDS at room temperature and with 0.1× SSC containing 0.1% SDS at 60 °C for 30 min. Dried membranes were exposed to Kodak XAR-5 film with intensifying screens at -70 °C. Hybridization intensities were quantified by a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA). The intensity of the c-fos mRNA signal was normalized for possible differences in mRNA loading or transfer by dividing its value by the intensity of the L30 ribosomal protein mRNA.

Statistical Analysis-- Unpaired t tests were performed to test the differences between the groups (with exogenous apoE versus without exogenous apoE or E- cells versus E+ cells). A significance of difference was determined at the p < 0.05 level.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation of ApoE-expressing Cell Lines-- To compare the effects of exogenous apoE added to cells via the culture medium with the effects of endogenous apoE (synthesized in and secreted from cells), we established stably transfected derivatives of the rat F111 embryonic fibroblast cell line. Multiple clones were isolated that expressed either apoE and hygromycin resistance (referred to as E+ cells) or hygromycin resistance only (referred to as E- cells). We confirmed that E+ cells synthesized and secreted apoE by immunoblot analyses of whole cell extracts and concentrated conditioned medium from these clones (Fig. 1A) and by indirect immunofluorescence (Fig. 1B). E+ cells synthesized and secreted an ~34-kDa protein that comigrated with purified apoE. Based on the signal intensities of apoE standards obtained in these immunoblots, we estimate that E+ cells secrete ~40 ng of apoE/106 cells/day and contain ~25 ng of intracellular apoE/mg of total cell protein. No apoE, either intracellular or secreted, was detected in E- cell cultures. Although E+ cells clearly secrete apoE, cell-associated apoE was not localized with the Golgi apparatus (Fig. 1, B and C). It is also noteworthy that little apoE was detected at the cell surface (Fig. 1B).


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 1.   ApoE expression and cellular localization. A, cells and media were harvested after 24 h in serum-free DMEM, followed by the collection of media and extraction of cell proteins. Equal amounts (40 µg of cell protein extracts or 40 µl of 10× concentrated culture medium) of samples were loaded onto SDS-12% polyacrylamide gels. ApoE was detected by immunoblotting with monoclonal antibody E10 and the ECL reaction. Lane 1, recombinant apoE (1 ng) as a positive control; lane 2, E- cell protein extract; lane 3, E+ cell protein extract; lane 4, conditioned medium from E- cells; lane 5, conditioned medium from E+ cells. B and C, shown is the dual labeling of permeabilized and fixed E+ cells: endogenous apoE (rhodamine) (B) and NBD-C6-labeled Golgi apparatus (C).

Interesting morphological changes were observed in E+ cells. Compared with E- cells (Fig. 2A), E+ cells (Fig. 2C) had shorter cell bodies, resulting in a more oval shape, as well as less distinct nuclear boundaries when viewed by phase-contrast microscopy and a prominent perinuclear accumulation of phase-bright vesicles. Despite the above changes, similar to E- cells (Fig. 2B), E+ cells maintained a prominent actin filament network (Fig. 2D). In E+ cells (Fig. 2G), the perinuclear accumulation and increase in size of phase-bright vesicles relative to similar vesicles in E- cells (Fig. 2E) were more apparent when viewed by differential interference contrast microscopy. In E- (Fig. 2, E and F) and E+ (G and H) cells, these vesicles were not co-localized with the Golgi apparatus. However, these vesicles did stain positive with Nile red (data not shown), indicating the presence of neutral lipid. Despite the apparent formation of larger lipid-containing vesicles or droplets in E+ cells, there was no measurable difference in whole cell lipid content (triglyceride and cholesterol ester) between E+ and E- cells (data not shown).


View larger version (101K):
[in this window]
[in a new window]
 
Fig. 2.   ApoE expression alters cellular morphology. Shown are the results from morphological analyses of E- (A, B, E, and F) and E+ (C, D, G, and H) cells by phase-contrast (A and C; magnification × 100), fluorescence (B and D, actin staining; F and H, Golgi staining with NBD-C6; magnification × 400), and differential interference contrast (E and G; magnification × 400) microscopy. Phase-contrast, differential interference contrast, and NBD-C6 fluorescent images were gathered on live cells. The actin network was visualized following staining of fixed cells with actin-BODIPY-phallacidin. In E-H, perinuclear localization of the Golgi apparatus is asymmetric and indicated by asterisks. Neutral lipid-containing vesicles (see "Results") are indicated by arrowheads.

The same morphological changes were seen in each of three independent E+ clonal isolates, but were never seen in E- cells exposed to 10 µg/ml exogenous apoE, even after prolonged periods (up to 14 days). Thus, the presence of apoE within these fibroblasts had substantial effects on cellular architecture that could not be mimicked by exposure to exogenous apoE.

ApoE Inhibits F111 Cell Proliferation-- To determine whether apoE (both exogenous and endogenous) has a sustained effect on cell proliferation, we compared the proliferation rate of E- cells, in the presence or absence of exogenous apoE, with that of E+ cells over a period of 14 days (Fig. 3). Cells that expressed apoE had significantly slower proliferation rates during mid-to-late log growth (days 5-11) (Fig. 3A). Very similar results were seen when exogenous apoE was added to the growth medium of E- cells (data not shown). In both cases, apoE increased population doubling times by 30-50%, resulting in a 4-7-fold reduction in cell number on days 5 and 7 (Fig. 3B). Despite the reduction in proliferation rates by day 14, the cell densities of apoE-exposed cultures were equal to the saturation density of cultures not exposed to apoE. Therefore, apoE expression or addition to the culture medium did not arrest cell proliferation.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   ApoE slows proliferation by prolonging the G1 phase of the cell cycle. Cells were plated on day 0 in the growth medium in the absence or presence of 10 µg/ml apoE. For cells treated with exogenous apoE, fresh apoE was added at every media change. Cells were trypsinized and counted (A and B) or stained with propidium iodide and subjected to fluorescence-activated cell sorter analysis (C). In A, growth rates are shown for E- (open circle ) and E+ () cells. Asterisks represent time points at which E- and E+ cell numbers differed significantly (p < 0.01). In B, the data obtained at days 5 and 7 for E- cells (with or without exogenous (exog.) apoE) and E+ cells are compared. Asterisks indicate that cell numbers differed significantly from the untreated E- control cells (p < 0.05). In C, total DNA content was quantified in E- and E+ cells by measuring propidium iodide staining 48 h after stimulating cells with 5% calf serum. The number of cells in each phase of the cell cycle (based on total DNA content) was divided by the total number of cells monitored (gated total) and multiplied by 100 to derive percentages. Over the course of these experiments, apoE expression was associated with an increase in the percentage of cells in G1 (2N DNA content). These results are from three parallel experiments. The asterisk indicates that the percentage of cells in the G1 phase of the cell cycle differed significantly between E- and E+ cells (p < 0.01). The number sign indicates that the percentage of cells in the G2 phase (4N DNA content) differed significantly between E- and E+ cells (p < 0.01).

The increased population doubling time of apoE-exposed cells was associated with a prolongation of the G1 phase of the cell cycle. E- and E+ cells were fixed, and their DNAs were stained with propidium iodide 48 h after replating. Note that plating densities for this experiment were considerably higher than in the extended proliferation assays. As a result, by 48 h, cell populations were in early-to-mid log growth. Relative DNA content was quantified by flow cytometry (Fig. 3C). At 48 h post-plating, 70% of E- cells had a 2N DNA content (and thus were in the G0/G1 phase of the cell cycle), 18% had a 4N DNA content (G2/M phase), and 12% had DNA levels intermediate between 2N and 4N (cells in S phase). In contrast, 85% of the E+ cells were in G0/G1, with compensatory decreases in the number of cells in S phase (from 12 to 10%) and G2/M (from 18 to 5%; p < 0.05). There were few cells in either population with less than 2N DNA levels, indicating that apoE expression did not increase apoptotic DNA fragmentation.

ApoE Attenuates Growth Factor Signaling-- Prolongation of the G1 phase of the cell cycle is frequently associated with decreased responsiveness to mitogens. Indeed, several investigators have demonstrated that exogenous apoE inhibits short-term proliferative responses to mitogens of endothelial cells, Kaposi's sarcoma cells, and smooth muscle cells (4-6). To see whether exogenous apoE and endogenous apoE decreased F111 cell responsiveness to serum mitogens, we measured [3H]thymidine incorporation into E- cells, into E+ cells, and into E- cells treated with exogenous apoE. Cells were arrested in G0 by serum starvation (0.1% calf serum for 48 h) and grown in 0.1 or 10% calf serum and 1 µC/ml [3H]thymidine with or without exogenous apoE (10 µg/ml) for 40 h, and incorporation of [3H]thymidine was quantified. The results of these experiments uncovered two effects of apoE. First, total incorporation of [3H]thymidine into DNA and the -fold induction of [3H]thymidine incorporation in response to serum were significantly reduced by apoE (Fig. 4). Serum stimulated [3H]thymidine incorporation into E- cells by 25-fold. Exogenous apoE reduced the serum response of E- cells so that [3H]thymidine incorporation increased by only 7-fold. Serum treatment had modest effects on E+ cells, increasing [3H]thymidine incorporation by 4-fold. Second, in the presence of apoE (and in particular, endogenous apoE), serum-starved cells continued to incorporate [3H]thymidine into DNA. As a result, despite the pronounced decreases in -fold stimulation in response to serum treatment, apoE decreased overall thymidine incorporation only by 30% (exogenous apoE) or by 50% (endogenous apoE). Taken together with the previous data on population doubling times and cell cycle phase distribution, we conclude that apoE reduces (but does not eliminate) the ability of serum growth factors to drive progression of cells through G1.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   ApoE reduces serum-induced DNA synthesis. Cells were maintained in medium containing 0.1% calf serum (CS) for 48 h, at which time the medium was replaced with fresh medium containing 0.1 or 10% calf serum, 1 µCi/ml [3H]thymidine, and 10 µg/ml exogenous (exog.) apoE where indicated. After 40 h, acid-insoluble radioactivity was measured ([3H]thymidine incorporation).

ApoE Inhibits MAPK Activation, but Not c-fos Expression-- Among the major mitogens present in serum are peptide growth factors that are ligands for receptor tyrosine kinases, in particular, the potent fibroblast mitogen platelet-derived growth factor (PDGF). Numerous studies have established that growth factors drive G1 progression by activating cytosolic and nuclear protein kinases that subsequently activate specific transcription factors. Key targets include the p42 and p44 MAPKs and the c-fos proto-oncogene (39, 40). We determined whether apoE altered the overall levels of serum- or PDGF-induced tyrosine phosphorylation, MAPK activity, and c-fos expression. Cells (both E- and E+) were serum-starved for 48 h and then treated with either 10 ng/ml PDGF or 10% calf serum (with or without exogenous apoE) for 10 min. Both total tyrosine phosphorylation (Fig. 5A) and activated MAPK levels (Fig. 5B) were monitored by immunoblotting. Serum stimulation led to a rapid increase in tyrosine phosphorylation, in particular, of multiple high molecular mass proteins (>175 kDa). PDGF treatment had a similar, although less pronounced effect on total tyrosine phosphorylation. The most notable differences between serum and PDGF effects occurred in the high molecular mass proteins, consistent with the view that these changes likely represent autophosphorylation of a variety of receptor tyrosine kinases in response to the mixture of polypeptide growth factors present in serum. Similar responses to both serum stimulation and PDGF stimulation were seen in E+ and E- cells and in E- cells treated with exogenous apoE and PDGF.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of apoE on growth factor signaling. E- and E+ cells were maintained in 0.1% calf serum (CS) for 48 h. Cells were then stimulated with 10 ng/ml PDGF or 10% calf serum in the presence or absence of 10 µg/ml exogenous (exog.) apoE for 10 min. Tyrosine phosphorylation (A) and MAPK activation (B; amount of phospho-MAPK (MAPK-PO4) relative to the amount of total MAPK (MAPK-tol)) were assessed by immunoblotting. In C, serum-starved E- and E+ cells were treated with 0.1 or 3% calf serum ± 10 µg/ml exogenous apoE for 30 min, after which total RNA was extracted, and c-fos and L30 mRNA levels were determined by Northern blot analysis. ApoE (both exogenous and endogenous) prevented MAPK activation without detectably affecting tyrosine phosphorylation or c-fos mRNA expression.

When we looked specifically at activation of p42/p44 MAPKs by serum and PDGF, a different pictured emerged (Fig. 5B). Stimulation of E- cells resulted in activation of MAPK in a manner that paralleled overall changes in tyrosine phosphorylation. Either in E+ cells or when added to E- cells, apoE dramatically reduced the activation of MAPK. This was true in response to both PDGF and serum stimulation.

In many situations, following activation in the cytosol, MAPKs translocate to the nucleus and contribute to transcriptional regulation of target genes. Following mitogenic stimulation of resting cells, critical nuclear targets are the immediate-early growth response genes, including the c-fos proto-oncogene. Increased c-fos mRNA levels were seen within 15 min of stimulating serum-starved E- cells as well as E+ cells. Peak c-fos mRNA levels were reached 30 min after stimulation. Despite the effects of apoE on [3H]thymidine incorporation, cell cycle progression, and MAPK documented above, no inhibition of c-fos induction was observed in the presence apoE (Fig. 5C).

Vogel et al. (4) previously proposed that apoE inhibits proliferation by competing with fibroblast growth factors for heparin binding. This model leads to the prediction that at a fixed concentration of apoE, increased levels of growth factor should increase proliferation. We tested this prediction by measuring the proliferation of E- cells, of E- cells treated with apoE (10 µg/ml), and of E+ cells in different serum concentrations (Fig. 6). The proliferation rate of E- cells, either in the absence or presence of exogenous apoE, increased incrementally in response to increases in serum from 2.5 to 10%. At days 7 and 9, each 2-fold increase in serum concentration resulted in an ~1.6-fold increase in cell number (Fig. 6, A and B). In contrast, the proliferation rate of E+ cells was much less dependent on serum concentration. As shown in Fig. 6C, the increase in serum concentration from 2.5 to 10% did not significantly increase cell number on day 7 or 9. Note that the number of E- cells is three to seven times more than the number of E+ cells under each condition at days 7 and 9. Therefore, although it is possible that competition with fibroblast growth factor or other serum factors for heparin-binding sites might explain part of the anti-proliferative effect of apoE, it is unlikely to account for all of the actions of apoE, in particular, when apoE is expressed endogenously.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Endogenous apoE inhibits serum effects on cell proliferation. E- cells (A), E- cells treated with 10 µg/ml exogenous apoE (B), and E+ cells (C) were grown in medium supplemented with 2.5% (open bars), 5% (hatched bars), or 10% (closed bars) calf serum (CS). After day 7 or 9, total cell numbers were counted. For each 2-fold increase in serum concentrations, E- cell numbers increased (~1.6-fold), whereas E+ cell numbers were unaffected by serum concentration. Asterisks indicate that the number of E- cells differed significantly between the 2.5 and 5% calf serum groups, and number signs indicate that the numbers differed between the 5 and 10% groups (p < 0.05). Note that at all serum concentrations, there were significantly fewer E+ cells than E- cells (p < 0.05; note the differences in the scale of the y axes in A and C).

ApoE Stimulates DNA Synthesis in the Absence of Serum-- In the presence of apoE, F111 cells had elevated levels of DNA synthesis in the absence of serum (Fig. 4, compare open bars). This latter result was examined in more detail (Fig. 7). First, we confirmed that apoE elevated basal [3H]thymidine incorporation in the absence of calf serum using three independent isolates (one pool of many clones, E--1 and E+-1; and two isolated clones, E--2, E--3, E+-2, and E+-3) of transfected cells expressing hygromycin resistance or expressing both hygromycin resistance and apoE. For the control cell lines, basal [3H]thymidine incorporation ranged from 4500 to 8000 dpm incorporated per dish. Addition of exogenous apoE variably increased [3H]thymidine incorporation, with responses ranging from 110% in clone E--1 to a 300% increase (from 5200 to 16,100 dpm) in clone E--3. In clonal isolates of apoE-expressing cells, basal [3H]thymidine incorporation was dramatically elevated. In these cells, incorporation ranged from 11,200 dpm/dish for the uncloned pool to ~30,000 dpm/dish for the clonal isolates. ApoE expression and secretion were quantified in the two monoclonal E+ cell lines. The two clones had comparable levels of cell-associated apoE (27.7 and 29.2 ng of apoE/mg of cell protein, respectively); however, the level of apoE in the conditioned medium from clone E+-3 (1700 ng of apoE/mg of cell protein) was about five times higher than in the medium from clone E+-2 (320 ng of apoE/mg of cell protein). Despite differences in apoE secretion, similar levels of DNA synthesis were observed in the two apoE-expressing clones. Therefore, apoE has two apparently disparate effects on proliferation. On the one hand, apoE allowed serum-deprived cells to remain in the cell cycle. On the other hand, apoE extended the time of G1 progression, resulting in longer population doubling times. This effect was associated with significantly attenuated responses to serum growth factors and/or PDGF.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   ApoE enhances DNA synthesis in serum-deprived cells. Cells were maintained in 0.1% calf serum for 48 h and then incubated in fresh medium with 0.1% calf serum (CS), 1 µCi/ml [3H]thymidine, and 10 µg/ml exogenous apoE (E) where indicated for an additional 40 h. In parallel, apoE levels in cell extracts and conditioned media from clones E+-2 and E+-3 were quantified by densitometric scanning of immunoblots. These data are shown at the top and are expressed as nanograms of apoE. [3H]Thymidine incorporation was measured as described under "Results." Open bars, E- cells (E--1 pooled clones and E--2 and E--3 clonal isolates); hatched bars, E- cells treated with exogenous apoE; closed bars, E+ cells (E+-1 pooled clones and independent E+-2 and E+-3 clonal isolates). N.D., not determined.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we examined both long- and short-term effects of apoE on cell proliferation. In addition, we have systematically compared the effects of apoE added to growth medium with the effects of stably expressing apoE in target cells. Specifically, this study demonstrates that both endogenous apoE and exogenous apoE (a) decrease proliferation rates (but not to 0) over an extended period, (b) inhibit activation of MAPKs and stimulation of DNA synthesis by serum, and (c) increase DNA synthesis in serum-deprived cells.

Our results also confirm the data of others (4-6) demonstrating that apoE, independently of its role in lipid transport and metabolism, exerts an anti-proliferative effect on cells and attenuates serum growth factor signaling. However, our results extend these previous studies in three important ways. First, we demonstrated that the effects of exogenous apoE and endogenous apoE differ in both quantitative and qualitative ways. These differences are likely to reflect underlying differences in the mechanism of apoE action when presented to cells in these distinct ways. Second, we demonstrated that the effects of apoE are prolonged. A significant finding in this respect is that apoE exposure does not result in growth arrest. Although apoE prolongs progression through the G1 phase of the cell cycle, it does not cause cells to exit the cycle and become quiescent or to stop at either the G1/S or G2/M checkpoint. Third, apoE (in particular, endogenous apoE) dissociates serum growth factor signaling from cell proliferation. This is evident when one considers both the inhibitory effect of apoE on serum-stimulated progression from G0 through G1 and into S phase and the observation that E+ cells continue to synthesize significant amounts of DNA in the near absence of serum growth factors.

Do Exogenous ApoE and Endogenous ApoE Act via Distinct Mechanisms?-- In a previous study comparing the effects of exogenous apoE and endogenous apoE on lipoprotein uptake and metabolism by mouse macrophages, we demonstrated clear differences in the response to apoE from these different sources (28, 29). We attributed the difference in action to the restriction of exogenous apoE and endogenous apoE to distinct subcellular compartments; exogenous apoE was detected in endocytic vesicles, whereas endogenous apoE was found in the secretory pathway. In this study, exogenous apoE and endogenous apoE shared the ability to slow proliferation rates, to elevate (or sustain) basal DNA synthesis in low serum, and to inhibit acute growth factor signaling. Endogenous apoE was more effective than exogenous apoE in eliciting the first two responses. It is clear that endogenous apoE can affect additional cellular functions that are not sensitive to the amount of exogenous apoE used in this study, including changes in cellular morphology and the reduction in the requirement for serum mitogens. The broader action of endogenous apoE might result from its ability to target an additional signaling pathway (other than leading to MAPK activation). Recent studies have shown that apoE may inhibit cell proliferation through receptor-independent mechanisms (41), but modulate cell migration through apoE receptor-dependent pathways, although which of the family of apoE receptors is involved is not known (41, 42). Whether similar mechanisms are responsible for the effects of apoE on cell proliferation and the morphological changes observed in this study requires further investigation.

It is possible to explain the enhanced effectiveness of endogenous versus exogenous apoE on common targets by proposing that higher and more sustained concentrations of apoE at the cell surface were achieved following local synthesis and secretion than were achieved following addition of exogenous apoE to the culture medium. Human plasma contains ~36 µg/ml apoE, largely bound to lipoproteins (43). The minimal exogenous apoE concentration that consistently inhibited cell proliferation in our studies was 5 µg/ml, whereas E+ cells secreted on average only ~100 ng of apoE/ml/day. ApoE is a heparin-binding protein and therefore would be expected to stay bound to cell-surface heparin-containing proteoglycans. Such tight binding would result in an underestimation of the levels of apoE secreted, and the effective concentration acting on the cell surface would be significantly higher. However, immunological localization of apoE in E+ cells does not support this; the majority of apoE appeared to be cytoplasmic and not cell surface-associated (Fig. 1B). In macrophages, endogenous apoE and exogenous apoE follow separate intracellular trafficking routes. Endogenous apoE is associated with Golgi structures, whereas exogenous apoE is found in endocytic vesicles (28). In the E+ cells studied here, there was only minimal overlap between immunoreactive apoE and staining with Golgi markers (Fig. 1, B and C). Although these assays do not afford the resolution necessary to determine whether the bulk of endogenous apoE was cytosolic or vesicular (endocytic or pre-Golgi secretory), they raise the possibility that a significant fraction of endogenous apoE might be in a non-secretory compartment. We suggest it is likely that this intracellular apoE interacts with cytoskeletal components that are not accessible to exogenous apoE and that these interactions cause reorganization of cytoskeletal structures and alter signal transduction.

How Does ApoE Affect Proliferation?-- Two possible mechanisms have been proposed to account for the anti-proliferative affects of apoE. In one, apoE acts directly to inhibit growth factor signaling. Browning et al. (5) have proposed that apoE, by virtue of its high affinity for heparin sulfate, interferes with growth factor signaling by competing for cell-surface binding sites. This model is unlikely to explain our results for two reasons. First, this mechanism should be limited to inhibiting signaling by mitogens that depend on heparin sulfate binding for efficient signaling, e.g. the fibroblast growth factors. However, in our assays, apoE was broadly effective, blocking the action of the mixture of mitogens present in calf serum and the action of purified PDGF. Second, apoE (exogenous and endogenous) inhibited MAPK activation, but failed to prevent either serum or purified PDGF stimulation of tyrosine phosphorylation or induction of c-fos expression. We showed previously that transcriptional activation of c-fos in F111 cells depends predominantly on signaling to the nucleus via phosphatidylinositol 3-kinase and c-Jun N-terminal kinase (21). Therefore, the different effect of apoE on MAPK activation and c-fos induction indicates that only a specific subset of signaling pathways activated by receptor tyrosine kinases are affected by apoE.

Paka et al. (44) have proposed an alternative mechanism in which apoE exerts a positive effect on synthesis of the heparin sulfate proteoglycan perlecan, which exerts the measured anti-proliferative effects on apoE. Although we cannot rule out a role for perlecan in mediating the sustained effects of apoE (especially in E+ cells), the ability of exogenous apoE to rapidly inhibit growth factor signaling is not compatible with the delay (24-48 h) required for increased expression and synthesis of perlecan (44).

At present, we do not know how apoE disrupts growth factor signaling. An important clue might come from our demonstration that although apoE expression slows proliferation and inhibits mitogenic signaling, it does not result in growth arrest. Indeed, apoE expression enhances aspects of proliferation, notably DNA synthesis in the absence of external mitogens. Two precedents for such apparently dichotomous activities are worth noting. The first precedent comes from results that closely parallel ours, in which Chen and Gardner (45) demonstrated that retinoic acid has the ability both to stimulate mitogenesis of aortic smooth muscle cells and to inhibit the mitogenic action of endothelin on these same cells. Thus, retinoic acid inhibits signaling required for early G1 progression (mitogen activation of MAPK), but increases expression of cyclin D, which is required for the progression from late G1 into S phase. The second precedent comes from studies on oncogenic transformation. Acute expression of many oncogenes such as v-src and v-ras activates mitogenic signaling cascades and active transcription of target genes. However, in cells that have been transformed by stable expression of these proteins, signaling in response to exogenous growth factors is inhibited (46-48). It is possible that endogenous apoE acts in an analogous, albeit much more constrained manner, resulting in uncoupling of cell cycle progression from dependence on positive extracellular signals.

Abnormalities in the control of cell proliferation and differentiation are associated with a number of diseases, including atherosclerosis. Hyperproliferation of smooth muscle cells contributes to the progressive formation of atherosclerotic plaques (31). Accumulation of apoE in atherosclerotic lesions (32) is believed to be anti-atherogenic by promoting cellular cholesterol efflux and increasing lipid metabolism (7, 10). The previous observation that apoE inhibits smooth muscle cell proliferation (6) and our current finding that the anti-proliferative effect of apoE is sustained over long periods provide an additional mechanism for the anti-atherogenic action of apoE.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants HL40404 and CA79737, National Livestock and Meat Board Grant 6-41809, an American Institute of Nutrition predoctoral fellowship (to Y.-Y. H.), and American Cancer Society Grant RPG-95-024-03.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Dept. of Neurology, Columbia University, NI 9-100, 710 W. 168th St., New York, NY 10032.

|| Present address: Dept. of Neuroscience, Johns Hopkins University School of Medicine, PCTB 1004, 725 N. Wolfe St., Baltimore, MD 21205.

Dagger Dagger To whom correspondence should be addressed: Inst. of Human Nutrition, Columbia University, HHSC 5-503, 701 W. 168th St., New York, NY 10032. Tel.: 212-305-2107, Fax: 212-305-3079; E-mail: dat1@columbia.edu.

Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M105325200

    ABBREVIATIONS

The abbreviations used are: apoE, apolipoprotein E; MAPK, mitogen-activated protein kinase; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; NBD-C6, NBD-C6-ceramide, 6-(cN-(7-nitrobenz-z-oxa-1,3-diazol-4-gl)amino)hexanoyl)sphingosine; MOPS, 3-(N-morpholino)propanesulfonic acid; PDGF, platelet-derived growth factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Mahley, R. W. (1988) Science 240, 622-630[Abstract/Free Full Text]
2. Roses, A. D., Saunders, A. M., Corder, E. H., Pericak-Vance, M. A., Han, S. H., Einstein, G., Hulette, C., Schmechel, D. E., and Huang, D. (1995) Arzneim. Forsch. 45, 413-417[Medline] [Order article via Infotrieve]
3. Lin, C. Y., Lucas, M., and Mazzone, T. (1998) J. Lipid Res. 39, 293-301[Abstract/Free Full Text]
4. Vogel, T., Guo, N., Guy, R., Drezlich, N., Krutzsch, H. C., Blake, D. A., Panet, A., and Roberts, D. D. (1994) J. Cell. Biochem. 54, 299-308[CrossRef][Medline] [Order article via Infotrieve]
5. Browning, P. J., Roberts, D. D., Zabrenetzky, V., Bryant, J., Kaplan, M., Washington, R. H., Panet, A., Gallor, R. C., and Vogel, T. (1994) J. Exp. Med. 180, 1949-1954[Abstract/Free Full Text]
6. Ishigami, M., Swertfeger, D. K., Granholm, N. A., and Hui, D. Y. (1998) J. Biol. Chem. 273, 20156-20161[Abstract/Free Full Text]
7. Mazzone, T., and Reardon, C. (1994) J. Lipid Res. 35, 1345-1353[Abstract]
8. Basu, S. K., Brown, M. S., Havel, R. J., and Goldstein, J. L. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 7545-7549[Abstract/Free Full Text]
9. Dory, L. (1991) J. Lipid Res. 32, 783-792[Abstract]
10. Schweigelshohn, B., Presley, J. F., Gorecki, M., Vogel, T., Carpentier, Y. A., Maxfield, F. R., and Deckelbaum, R. J. (1995) J. Biol. Chem. 270, 1761-1769[Abstract/Free Full Text]
11. Weisgraber, K. H., Rall, S. C., Mahley, R. W., Marcel, Y. L., and Sparrow, J. T. (1986) J. Biol. Chem. 261, 2068-2076[Abstract/Free Full Text]
12. Dahan, S., Ahluwalia, J. P., Wong, L., Posner, B. I., and Bergeron, J. J. (1994) J. Cell Biol. 127, 1859-1869[Abstract/Free Full Text]
13. Granot, E., and Eisenberg, S. (1995) Atherosclerosis 114, 115-122[CrossRef][Medline] [Order article via Infotrieve]
14. Majack, R. A, Castle, C. K., Goodman, L. V., Weisgraber, K. H., Mahley, R. W., Shooter, E. M., and Gebicke-Haerter, P. J. (1988) J. Cell Biol. 107, 1207-1213[Abstract/Free Full Text]
15. Auwerx, J. H., Deeb, S., Brunzell, J. D., Peng, R., and Chait, A. (1988) Biochemistry 27, 2651-2655[CrossRef][Medline] [Order article via Infotrieve]
16. Crespo, P., Delgado, M. D., Gomez-Casares, M. T., Cuadrado, M. A., Richard, C., and Leon, J. (1993) Leuk. Res. 17, 771-776[CrossRef][Medline] [Order article via Infotrieve]
17. Reyland, M. E., and Williams, D. L. (1991) J. Biol. Chem. 266, 21099-21104[Abstract/Free Full Text]
18. Reyland, M. E., Prack, M. M., and Williams, D. L. (1992) J. Biol. Chem. 267, 17933-17938[Abstract/Free Full Text]
19. Talmage, D. A., and Lackey, R. S. (1992) Oncogene 7, 1837-1845[Medline] [Order article via Infotrieve]
20. Talmage, D. A., Riney, C., and Benjamin, T. L. (1991) Cell Growth Differ. 2, 51-58[Abstract]
21. Chen, Y., Freund, R., Listerud, M., Wang, Z., and Talmage, D. A. (1999) Oncogene 18, 139-148[CrossRef][Medline] [Order article via Infotrieve]
22. Deleted in proof
23. Deleted in proof
24. Deleted in proof
25. Deleted in proof
26. Deleted in proof
27. Deleted in proof
28. Ho, Y.-Y., Al-Haideri, M., Mazzone, T., Vogel, T., Presley, J. F., Sturley, S., and Deckelbaum, R. J. (2000) Biochemistry 39, 4746-4754[CrossRef][Medline] [Order article via Infotrieve]
29. Mamdouh, Z., Deckelbaum, R. J., Seo, T., Maxfield, F. R., Vogel, T., and Al-Haideri, M. (2000) Circulation 98, II-87 (Abstr. 420)
30. Deleted in proof
31. Garcia, J. H., and Khang-Loon, H. (1996) Neuroimaging Clin. N. Am. 6, 801-810[Medline] [Order article via Infotrieve]
32. Rosenfeld, M. E., Butler, S., Ord, V. A., Lipton, B. A., Dyer, C. A., Curtiss, L. K., Palinski, W., and Witztum, J. L. (1993) Arterioscl. Thromb. 13, 1382-1389[Abstract/Free Full Text]
33. Mazzone, T., Pustelnikas, L., and Reardon, C. A. (1992) J. Biol. Chem. 267, 1081-1087[Abstract/Free Full Text]
34. Khuri, F. R., Cho, Y., and Talmage, D. A. (1996) Cell Growth Differ. 7, 595-602[Abstract]
35. Radloff, R., Bauer, W., and Vinograd, J. (1967) Proc. Natl. Acad. Sci. U. S. A. 57, 1514-1521[Free Full Text]
36. Chen, C., and Okayama, H. (1988) BioTechniques 6, 632-638[Medline] [Order article via Infotrieve]
37. Seitz, W. R. (1984) Clin. Biochem. 17, 120-125[CrossRef][Medline] [Order article via Infotrieve]
38. Feinberg, A. P., and Vogelstein, B. (1983) Anal. Biochem. 132, 6-13[CrossRef][Medline] [Order article via Infotrieve]
39. De Vivo, M., and Iyengar, R. (1994) J. Biol. Chem. 269, 19671-19674[Abstract/Free Full Text]
40. Thommes, K. B., Hoppe, J., Vetter, H., and Sachinidis, A. (1996) Exp. Cell Res. 226, 59-66[CrossRef][Medline] [Order article via Infotrieve]
41. Swertfeger, D. K., and Hui, D. Y. (2001) J. Biol. Chem. 276, 25043-25048[Abstract/Free Full Text]
42. Herz, J., and Beffert, U. (2000) Nat. Rev. Neurosci. 1, 51-58[CrossRef][Medline] [Order article via Infotrieve]
43. Rifai, N., and Silverman, L. M. (1987) Clin. Chim. Acta 163, 207-213[CrossRef][Medline] [Order article via Infotrieve]
44. Paka, L., Goldberg, I. J., Obunike, J. C., Choi, S. Y., Saxena, U., Goldberg, I. D., and Pillarisetti, S. (1999) J. Biol. Chem. 274, 36403-36408[Abstract/Free Full Text]
45. Chen, S., and Gardner, D. G. (1998) J. Clin. Invest. 102, 653-662[Medline] [Order article via Infotrieve]
46. Osei-Frimpong, J., Sepulveda, J., Rangdaeng, S., and Lebovitz, R. M. (1994) Mol. Carcinog. 10, 72-81[Medline] [Order article via Infotrieve]
47. Lucibello, F. C., Lowag, C., Neuberg, M., and Muller, R. (1989) Cell 59, 999-1007[CrossRef][Medline] [Order article via Infotrieve]
48. Sassone-Corsi, P., Sisson, J. C., and Verma, I. M. (1988) Nature 334, 314-319[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
D. E. Dove, M. F. Linton, and S. Fazio
ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects
Am J Physiol Cell Physiol, March 1, 2005; 288(3): C586 - C592.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-C. Chen, G. Pohl, T.-L. Wang, P. J. Morin, B. Risberg, G. B. Kristensen, A. Yu, B. Davidson, and I.-M. Shih
Apolipoprotein E Is Required for Cell Proliferation and Survival in Ovarian Cancer
Cancer Res., January 1, 2005; 65(1): 331 - 337.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Z. W.Q. Moore, B. Zhu, D. G. Kuhel, and D. Y. Hui
Vascular Apolipoprotein E Expression and Recruitment from Circulation to Modulate Smooth Muscle Cell Response to Endothelial Denudation
Am. J. Pathol., June 1, 2004; 164(6): 2109 - 2116.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Lutz, J. Nimpf, M. Jenny, K. Boecklinger, C. Enzinger, G. Utermann, G. Baier-Bitterlich, and G. Baier
Evidence of Functional Modulation of the MEKK/JNK/cJun Signaling Cascade by the Low Density Lipoprotein Receptor-related Protein (LRP)
J. Biol. Chem., November 1, 2002; 277(45): 43143 - 43151.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Boucher, P. Liu, M. Gotthardt, T. Hiesberger, R. G. W. Anderson, and J. Herz
Platelet-derived Growth Factor Mediates Tyrosine Phosphorylation of the Cytoplasmic Domain of the Low Density Lipoprotein Receptor-related Protein in Caveolae
J. Biol. Chem., May 3, 2002; 277(18): 15507 - 15513.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/46/43455    most recent
M105325200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, Y.-Y.
Right arrow Articles by Talmage, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, Y.-Y.
Right arrow Articles by Talmage, D. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement